Indian government committee calls for Johnson & Johnson to pay patients for recalled hip implants

The Central Drugs Standard Control Organization committee report suggested a base payment of about $28,300 per patient, with final totals decided individually. (Pixabay)

A panel convened by the Indian drug and medical device regulator has recommended Johnson & Johnson compensate each Indian patient that had to undergo revision surgeries or suffered adverse reactions to its metal-on-metal hip implants recalled in August 2010.

J&J’s DePuy unit recalled 93,000 ASR hip replacement systems worldwide after data emerged showing earlier-than-expected replacement surgeries following implantation, with a 12% failure rate within five years in devices designed to last for two decades.

The company would later look to spend nearly $3 billion to settle and resolve claims stemming from more than 10,000 lawsuits, and J&J abandoned sales of metal hip replacements in 2013. In India, about 4,700 procedures were performed since they were made available in 2004.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

After over a year of deliberation, the federal Central Drugs Standard Control Organization’s (CDSCO's) committee issued a 121-page report calling for a base payment of at least about $28,300 per patient, with final totals decided individually, and an extension of the company’s reimbursement program through 2025.

The ASR all-metal implant
(J&J)

RELATED: J&J's DePuy comes under fire for all-metal hip manufacturing in U.K.

The committee also recommended the creation of an independent government registry for tracking the usage of high-risk medical devices, analyzing performance and usage, and potentially with legal backing to issue warnings and alerts to manufacturers—as well as CDSCO guidance on effective device recall practices.

In addition, ASR patients should have their health checked every year, including routine physical follow-ups, x-rays and soft tissue imaging, as well as blood tests for levels of cobalt and chromium from the metal implant.

Suggested Articles

PPD, which is going public (again) after years of being private, is ramping up its clinical research units (CRUs).

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.